戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                          Human subjects with pseudohypoaldosteronism-1 because of loss-of-function mu
2 ace damage that phenocopied aspects of human pseudohypoaldosteronism-1 MG disease and was sex depende
3 neralocorticoid deficiency or excess, termed pseudohypoaldosteronism and Liddle's syndrome, respectiv
4 ation in the CD and demonstrated features of pseudohypoaldosteronism, including hyperkalemia, hyperal
5                 Secondary hypoaldosteronism (pseudohypoaldosteronism) occurs as a consequence of muta
6                                              Pseudohypoaldosteronism (PHA) types I and II are curious
7                           Autosomal dominant pseudohypoaldosteronism type 1 (adPHA1) is a rare condit
8                                     Systemic pseudohypoaldosteronism type 1 (PHA-1) is a severe salt-
9 epithelial Na(+) channel (ENaC) containing a pseudohypoaldosteronism type 1 (PHA-1)-causing missense
10                                              Pseudohypoaldosteronism type 1 (PHA1, OMIM 264350) is a
11                                              Pseudohypoaldosteronism type 1 (PHA1, OMIM 264350) is an
12 cient mice is similar to that of humans with pseudohypoaldosteronism type 1 and may provide a useful
13 unction leads to severe disorders, including pseudohypoaldosteronism type 1 and respiratory distress.
14                                        Renal pseudohypoaldosteronism type 1 is a rare autosomal-domin
15 ia and hyponatremia from autosomal recessive pseudohypoaldosteronism type 1 requiring aggressive ther
16 urface epithelium, leading to colon-specific pseudohypoaldosteronism type 1 with mineralocorticoid re
17 on is associated with respiratory disorders, pseudohypoaldosteronism type 1, and Liddle syndrome.
18 o adverse cardiovascular outcome occurred in pseudohypoaldosteronism type 1, but rather an improved d
19 n of a ubiquitous long WNK1 transcript cause pseudohypoaldosteronism type 2 (PHA II), characterized b
20 ns of 2 family members, WNK1 and WNK4, cause pseudohypoaldosteronism type 2 (PHA2), an autosomal-domi
21 ertension and hyperkalemia syndrome known as pseudohypoaldosteronism type 2 (PHA2).
22 ension and hyperkalemia (Gordon syndrome, or pseudohypoaldosteronism type 2).
23  of WNK1 that increase WNK1 transcript cause pseudohypoaldosteronism type 2, an autosomal-dominant di
24                                              Pseudohypoaldosteronism type I (PHA1) is characterized b
25 notypes dominated by renal disease (systemic pseudohypoaldosteronism type I and Liddle syndrome).
26 ubunits can lead to the salt wasting disease pseudohypoaldosteronism type I, associated with decrease
27 tion in alleviating human disease, including pseudohypoaldosteronism type I, hypotension, and neonata
28 ating that leads to the salt-wasting disease pseudohypoaldosteronism type I, was rescued by S3969.
29                   A rare Mendelian syndrome--pseudohypoaldosteronism type II (PHA-II)--features hyper
30                                              Pseudohypoaldosteronism type II (PHAII) is a rare Mendel
31                                              Pseudohypoaldosteronism type II (PHAII) is an autosomal
32  work has shown that mutations in WNK4 cause pseudohypoaldosteronism type II (PHAII), a disease featu
33                      Mutations in WNK4 cause pseudohypoaldosteronism type II (PHAII), a disease featu
34           Mutations in the kinase WNK4 cause pseudohypoaldosteronism type II (PHAII), a disease featu
35 lysine (K) at a key catalytic residue] cause pseudohypoaldosteronism type II (PHAII), a Mendelian dis
36                                              Pseudohypoaldosteronism type II (PHAII), a rare Mendelia
37 s in the gene encoding the kinase WNK4 cause pseudohypoaldosteronism type II (PHAII), a syndrome feat
38 e kinases, have recently been shown to cause pseudohypoaldosteronism type II (PHAII), an autosomal do
39 delian hypertensive and hyperkalemic disease pseudohypoaldosteronism type II (PHAII).
40                                              Pseudohypoaldosteronism type II (PHAII, also known as fa
41 butes to the pathogenesis of hypertension in pseudohypoaldosteronism type II caused by WNK1 and, poss
42          When Wnk4(D561A/+) mice, a model of pseudohypoaldosteronism type II expressing an activated
43                                              Pseudohypoaldosteronism type II is a salt-sensitive form
44 xcessive sodium retention, and hypertension (pseudohypoaldosteronism type II or Gordon's syndrome).
45 ene result in its overexpression and lead to pseudohypoaldosteronism type II, a disease with salt-sen
46 e the expression of WNK1 in humans and cause pseudohypoaldosteronism type II, a form of hypertension.
47 ine kinase WNK4 [with no lysine (K) 4] cause pseudohypoaldosteronism type II, a Mendelian disease fea
48          Here, we identify two genes causing pseudohypoaldosteronism type II, a Mendelian trait featu
49 o its overexpression and are responsible for pseudohypoaldosteronism type II, an autosomal dominant d
50  The discovery of four genes responsible for pseudohypoaldosteronism type II, or familial hyperkalemi
51 g WNK4, cause hypertension and hyperkalemia (pseudohypoaldosteronism type II, PHAII) by altering rena
52 und in a group of hypertensive patients with pseudohypoaldosteronism type II.
53 linked to a hereditary form of hypertension, pseudohypoaldosteronism type II.
54 on at this residue corrects the phenotype of pseudohypoaldosteronism type II.
55 mately 2.0% per minute) reported in systemic pseudohypoaldosteronism, which has loss-of-function muta